Codeine — 3-Methylmorphine (Opioid Prodrug · Antitussive · CYP2D6 · Informational)
| Compound | Codeine (3-Methylmorphine) |
| Chemical class | Alkaloid — Isoquinoline / Morphinan (3-O-Methylmorphine; weak opioid prodrug) |
| CAS | 76-57-3 |
| Primary source | Papaver somniferum (opium, 0.3–3% of latex); also semi-synthetic from morphine methylation |
| Key applications | OTC/prescription antitussive, mild analgesic; controlled substance; informational reference |
| Claim strength | High (as pharmaceutical antitussive/analgesic); Informational only |
| Typical form | Pharmaceutical tablet, syrup, combination products (codeine + paracetamol, codeine + ibuprofen) |
| Buy from Herbuno | Browse HerbIQ Compound Index → |
Name origin: From Greek kodeia = poppy head. Codeine was isolated from opium by Pierre-Jean Robiquet in 1832, shortly after morphine’s isolation. It is the 3-O-methyl ether of morphine — naturally present in opium at approximately 3–30× lower concentration than morphine. Most commercial codeine today is produced semi-synthetically by methylation of morphine. Pharmacology — prodrug mechanism: Codeine itself has very low affinity for opioid receptors. Its analgesic and antitussive effects are primarily mediated through hepatic CYP2D6-catalysed O-demethylation to morphine (approximately 10% of a codeine dose). The remaining codeine is metabolised to codeine-6-glucuronide (C6G, some opioid activity) and norcodeine (inactive). This prodrug mechanism has critical implications: CYP2D6 ultra-rapid metabolisers (~1–2% of Europeans, higher in some populations) convert codeine to morphine very rapidly, producing potentially toxic morphine plasma levels. CYP2D6 poor metabolisers (~7–10% of Europeans) derive no analgesic benefit from codeine. Major paediatric safety issue: Multiple deaths in children undergoing tonsillectomy receiving codeine for post-operative pain prompted FDA black box warning (2013) and Canadian ban (2013) on codeine in children under 12. WHO in 2015 recommended against codeine use in children. Regulatory status: Schedule II/V controlled substance depending on formulation (US); Schedule 4/equivalent in most markets. Pharmacy-only or prescription in most jurisdictions.
Codeine — Pharmacological and Clinical Context
Antitussive mechanism: Codeine’s antitussive effect (cough suppression) is mediated both by its conversion to morphine (mu-opioid receptor-mediated cough suppression in the brainstem) and by direct sigma receptor activity of codeine itself. It is the benchmark antitussive in clinical research — comparative trials for new antitussives use codeine as the positive control. Pharmaceutical evidence: High.
Analgesic (as morphine prodrug): Codeine’s analgesic effect is entirely dependent on CYP2D6-mediated conversion to morphine. At 60 mg oral codeine (standard analgesic dose), approximately 6 mg morphine is generated in extensive metabolisers — providing mild-to-moderate analgesia. Codeine is on the WHO pain ladder Step 2 (mild opioid for moderate pain), a position now questioned given the pharmacogenetic variability. Pharmaceutical evidence: High (but population-dependent).
CYP2D6 pharmacogenetics — critical clinical relevance: No other widely-used drug illustrates pharmacogenetic principles as clearly as codeine. FDA now requires CYP2D6 genotyping consideration for codeine in specific populations. Poor metabolisers (PM, ~7–10% European/Asian): no analgesic benefit, still exposed to GI effects. Extensive metabolisers (EM): normal response. Ultra-rapid metabolisers (UM, ~1–2% European, ~5–29% African, ~1–7% Middle Eastern): dangerous morphine accumulation, respiratory depression risk. Critical pharmacogenetic reference.
This compound is documented for research and formulator education purposes. For commercially available botanical ingredients, explore the HerbIQ Compound Index →
Frequently Asked Questions — Codeine
Why was codeine banned for children after tonsillectomies?
Several deaths occurred in children after tonsillectomy/adenoidectomy when they received codeine for post-operative pain management. Investigation revealed these children were CYP2D6 ultra-rapid metabolisers — they converted codeine to morphine at 2–5× the normal rate. Combined with post-surgical fluid restriction and sleep apnoea (common in children undergoing tonsillectomy for sleep-disordered breathing), the rapid morphine accumulation caused fatal respiratory depression. This was one of the most impactful pharmacogenetic adverse event discoveries in paediatric medicine.
Is codeine cough syrup addictive?
Yes — codeine is an opioid and carries addiction potential, including from antitussive cough syrup formulations. “Lean” (codeine cough syrup mixed with soda and candy) is a well-documented recreational drug abuse pattern associated with opioid dependence. The codeine in these preparations converts to morphine via CYP2D6, producing euphoria and opioid dependence. Many jurisdictions have restricted or eliminated OTC codeine-containing cough syrups as a result.
What replaced codeine on the WHO paediatric analgesic ladder?
WHO 2014 guidelines removed codeine from the paediatric pain ladder entirely, replacing it with: (1) strong opioids (morphine) for severe pain — morphine is safer than codeine in children because it does not depend on CYP2D6 conversion; (2) ibuprofen and paracetamol for mild-to-moderate pain. This is a counterintuitive but pharmacogenetically justified recommendation: the more potent opioid (morphine) is safer in children because it does not rely on variable CYP2D6 metabolism.
What natural compounds act as non-opioid antitussives?
Non-opioid botanical antitussives with some evidence: honey (particularly dark honey; multiple paediatric RCTs showing equivalence to dextromethorphan for acute cough); thyme extract (Thymus vulgaris); ivy leaf extract (Hedera helix, multiple RCTs for productive cough); liquorice root (glycyrrhizin demulcent effect). None matches codeine’s antitussive potency but all are appropriate for mild cough in contexts where opioid-class antitussives are not warranted.
Related compounds: Morphine, Noscapine, Thebaine, Narceine
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery